Kamil Stankowski

Dr. Kamil Stankowski

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
SFStefano Figliozzi
Stefano Figliozzi
EKEleni Kollia
Eleni Kollia
ASAlexandros Simistiras
Alexandros Simistiras
ACAntonia Camporeale
Antonia Camporeale
KSKamil Stankowski
Kamil Stankowski
GGGeorgios Georgiopoulos
Georgios Georgiopoulos
Purpose To perform a systematic review and meta-analysis to assess the effect of enzyme replacement therapy on cardiac MRI parameters in patients with Fabry disease. Materials and Methods A systematic literature search was conducted from January 1, 2000, through January 1, 2024, in PubMed, ClinicalTrials.gov, Embase, and Cochrane Library databases. Study outcomes were changes in the following parameters: (a) left ventricular wall mass (LVM), measured in grams; (b) LVM indexed to body mass index, measured in grams per meters squared; (c) maximum left ventricular wall thickness (MLVWT), measured in millimeters; (d) late gadolinium enhancement (LGE) extent, measured in percentage of LVM; and (e) native T1 mapping, measured in milliseconds. A random-effects meta-analysis of the pooled mean differences between baseline and follow-up parameters was conducted. The study protocol was registered in PROSPERO (CRD42022336223). Results The final analysis included 11 studies of a total of 445 patients with Fabry disease (mean age ± SD, 41 years ± 11; 277 male, 168 female). Between baseline and follow-up cardiac MRI, the following did not change: T1 mapping (mean difference, 6 msec [95% CI: -2, 15]; two studies, 70 patients, I2 = 88%) and LVM indexed (mean difference, -1 g/m2 [95% CI: -6, 3]; four studies, 290 patients, I2 = 81%). The following measures minimally decreased: LVM (mean difference, -18 g [95% CI: -33, -3]; seven studies, 107 patients, I2 = 96%) and MLVWT (mean difference, -1 mm [95% CI: -2, -0.02]; six studies, 151 patients, I2 = 90%). LGE extent increased (mean difference, 1% [95% CI: 1, 1]; three studies, 114 patients, I2 = 85%). Conclusion In patients with Fabry disease, enzyme replacement therapy was associated with stabilization of LVM, MLVWT, and T1 mapping values, whereas LGE extent mildly increased. Keywords: Fabry Disease, Enzyme Replacement Therapy (ERT), Cardiac MRI, Late Gadolinium Enhancement (LGE) Supplemental material is available for this article. © RSNA, 2024.

1 October 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
FTFrancesco Tartaglia
Francesco Tartaglia
GAGiulia Antonelli
Giulia Antonelli
MGMauro Gitto
Mauro Gitto
KSKamil Stankowski
Kamil Stankowski
DDDario Donia
Dario Donia
MCMauro Chiarito
Mauro Chiarito
Mitral regurgitation is the most common valve disease worldwide. Despite its wide success in inoperable or high-risk surgical patients, transcatheter edge-to-edge repair remains limited by some anatomic features and the non-negligible rate of significant residual regurgitation. Transcatheter mitral valve replacement has emerged as a viable alternative that promises to overcome these issues, but its development has been progressing slowly. This review aims to provide a comprehensive overview of the current state of transcatheter mitral valve replacement, including patient selection, procedural techniques, and currently available outcomes.

13 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KSKamil Stankowski
Kamil Stankowski
SFStefano Figliozzi
Stefano Figliozzi
VBVincenzo Battaglia
Vincenzo Battaglia
FCFederica Catapano
Federica Catapano
MFMarco Francone
Marco Francone
LMLorenzo Monti
Lorenzo Monti
Fabry disease (FD) is a genetic lysosomal storage disease with frequent cardiovascular involvement, whose presence is a major determinant of adverse clinical outcomes. As a potentially treatable cause of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction, the early recognition of FD is crucial to initiate enzyme replacement therapy and improve long-term prognosis. Multimodality imaging plays a central role in the evaluation of patients with FD and helps in the differential diagnosis of other conditions presenting with LVH. In the present review, we explore the current applications of multimodality cardiac imaging, in particular echocardiography and cardiovascular magnetic resonance, in the diagnosis, prognostic assessment, and follow-up of patients with FD.

KSKamil Stankowski
Kamil Stankowski
SFStefano Figliozzi
Stefano Figliozzi
CLCostanza Lisi
Costanza Lisi
FCFederica Catapano
Federica Catapano
CPCristina Panico
Cristina Panico
MFMarco Francone
Marco Francone
Cardiac magnetic resonance (CMR) has been recently implemented in clinical practice to refine the daunting task of establishing the risk of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). We present an exemplificative case highlighting the practical clinical utility of this imaging modality in a 24-year-old man newly diagnosed with an apical HCM. CMR was essential in unmasking a high risk of SCD, which appeared low-intermediate after traditional risk assessment. A discussion examines the essential role of CMR in guiding the patient’s therapy and underlines the added value of CMR, including novel and potential CMR parameters, compared to traditional imaging assessment for SCD risk stratification.

24 April 2024 in Medicina
Verified
Journal Article
Open access
PDF file
MMMaria Lo Monaco
Maria Lo Monaco
KSKamil Stankowski
Kamil Stankowski
SFStefano Figliozzi
Stefano Figliozzi
FNFlavia Nicoli
Flavia Nicoli
VSVincenzo Scialò
Vincenzo Scialò
MFMarco Francone
Marco Francone
Risk stratification for malignant ventricular arrhythmias and sudden cardiac death is a daunting task for physicians in daily practice. Multiparametric mapping sequences obtained via cardiovascular magnetic resonance imaging can improve the risk stratification for malignant ventricular arrhythmias by unveiling the presence of pathophysiological pro-arrhythmogenic processes. However, their employment in clinical practice is still restricted. The present review explores the current evidence supporting the association between mapping abnormalities and the risk of ventricular arrhythmias in several cardiovascular diseases. The key message is that further clinical studies are needed to test the additional value of mapping techniques beyond conventional cardiovascular magnetic resonance imaging for selecting patients eligible for an implantable cardioverter defibrillator.

15 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FCFrancesco Cannata
Francesco Cannata
KSKamil Stankowski
Kamil Stankowski
MGMichele Galasso
Michele Galasso
MMManuela Muratori
Manuela Muratori
EMElisabetta Mancini
Elisabetta Mancini
AMAntonio Mangieri
Antonio Mangieri
The growing awareness of tricuspid regurgitation (TR) and the fast-expanding array of devices aiming to percutaneously repair or replace the tricuspid valve have underscored the central role of multi-modality imaging in comprehensively assessing the anatomical and functional characteristics of TR. Accurate phenotyping of TR, the right heart, and pulmonary vasculature via echocardiography, computed tomography, and, occasionally, cardiovascular magnetic resonance and right heart catheterization is deemed crucial in choosing the most suitable treatment strategy for each patient and achieving procedural success. In the first part of the present review, key imaging factors for patient selection will be discussed. In the ensuing sections, an overview of the most commonly used, commercially available systems for transcatheter repair/replacement will be presented, along with their respective selection criteria and information on intraprocedural imaging guidance; these are edge-to-edge repair, orthotopic and heterotopic replacement, and valve-in-valve procedures.